Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.61 |
| ▸ | CES2 | O00748 | 2/20 | 0.61 |
| ▸ | METAP1 | P53582 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808965 | 1.00 | MIF (0.61) | MIFCES2METAP1ABCB1MAOB | |
| SCHEMBL6364740 | 0.92 | MAOB (0.65) | MIFCES2METAP1ABCB1MAOB | |
| SCHEMBL6364741 | 0.92 | MAOB (0.65) | MIFCES2METAP1ABCB1MAOB | |
| SCHEMBL6361474 | 0.86 | MAOB (0.67) | MIFMETAP1MAOBACHEMAOA | |
| SCHEMBL6361472 | 0.86 | MAOB (0.67) | MIFMETAP1MAOBACHEMAOA | |
| SCHEMBL7764041 | 0.84 | CES2 (0.62) | MIFCES2METAP1ABCB1MAOB | |
| SCHEMBL7764032 | 0.84 | CES2 (0.62) | MIFCES2METAP1ABCB1MAOB | |
| SCHEMBL29038294 | 0.82 | CES2 (0.80) | MIFCES2MAOBACHEMAOA | |
| SCHEMBL29038289 | 0.82 | CES2 (0.80) | MIFCES2MAOBACHEMAOA | |
| SCHEMBL8034937 | 0.80 | ACHE (0.56) | MIFCES2METAP1ABCB1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| EP-0700905-B1 | Tricyclic pyrazole derivatives | HOFFMANN LA ROCHE (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-5561150-A | 1-AMINOALKYL-1,4-DIHYDROINDENO(2,1-C)PYRAZOLES OR 1H-BENZ(G)INDAZOLES; SEROTONIN RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM, PSYCHOLOGICAL AND GASTROINTESTINAL DISORDERS | HOFFMAN-LA ROCHE INC. (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0700905-A1 | Tricyclic pyrazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1996-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | MIF 2828/4885CES2 3154/4885METAP1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.